Guifang Yu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Guifang Yu has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
Dongheng Yang
Guangdong Engineering Technology Research Center for Biological Targeting Diagnosis, Therapy, and Rehabilitation, Department of Oncology, The Fifth Affiliated Hospital, Guangzhou Medical University
4 shared publicationsHaoxin Lin
Guangdong Engineering Technology Research Center for Biological Targeting Diagnosis, Therapy, and Rehabilitation, Department of Oncology, The Fifth Affiliated Hospital, Guangzhou Medical University
4 shared publicationsNa Tao
Guangdong Engineering Technology Research Center for Biological Targeting Diagnosis, Therapy, and Rehabilitation, Department of Oncology, The Fifth Affiliated Hospital, Guangzhou Medical University
4 shared publicationsQunfeng Huang
Guangdong Engineering Technology Research Center for Biological Targeting Diagnosis, Therapy, and Rehabilitation, Department of Oncology, The Fifth Affiliated Hospital, Guangzhou Medical University
4 shared publicationsKailian Hou
Department of Oncology, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
3 shared publicationsWeiyi Li
Department of Oncology, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
3 shared publications
Latest Publications
- Open Access
- 28 January 2026
- Published by Frontiers Media SA in Frontiers in Molecular Biosciences
- Vol. 12
Plasmodium infection fully activates the immune system in peripheral blood and tumor microenvironment in a murine Lewis lung cancer model
Background: Plasmodium infection has been proven to activate antitumor immune responses. This study comprehensively analyzes the immune cell populations in peripheral blood and tumor microenvironment to elucidate the potential immunological mechanisms by which Plasmodium infection inhibits tumor growth. Methods: We established a subcutaneous Lewis lung cancer model in C57BL/6J mice and treated them with intraperitoneal injection of Plasmodium yoelii . The long and short diameters of tumors were measured. Then, high-dimensional flow cytometry was used to analyze the T cell subsets, macrophages and myeloid-derived suppressor cells (MDSCs) in peripheral blood and tumor tissues. Immunosuppression-related phosphorylated signal transducer and activator of transcription 3 (pSTAT3) and TGFβ in tumor tissues were also measured through Western blotting assay. Results: Plasmodium infection inhibited the growth of Lewis lung cancer in mice. The infection increased in the numbers of CD3 + T cells, including CD4 + and CD8 + T, CD4 + central memory T (Tcm), CD4 + effector memory T (Tem), CD8 + Tcm, CD8 + Tem, CD8 + virtual memory T (Tvm), CD8 + short-lived effector cells (SLEC), and CD8 + memory precursor effector cells (CD8 + MPEC) in peripheral blood. Concurrently, the infection also increased the numbers of CD3 + T cells, including CD4 + and CD8 + T, CD4 + Tcm, CD4 + Tem, CD4 + tissue resident memory T (Trm), CD8 + Tcm, CD8 + Tem, CD8 + Trm and CD8 + SLEC in tumor tissues. In addition, Plasmodium infection reduced the expression levels of PD-1 on CD4 + and CD8 + T, the number of polymorphonuclear MDSCs, and increased the ratio of M1/M2 macrophages in the tumor tissues. The initial mechanism study revealed that Plasmodium infection significantly reduced the expression levels of pSTAT3 and TGFβ in tumor tissues, providing direct evidence that Plasmodium infection activated the antitumor immune responses. Conclusion: Based on our past and current studies, we can draw the following conclusion: Plasmodium infection fully remodels and activates the immune system, targets and inhibits the entire tumor ecosystem through the key signals of pSTAT3 and TGFβ. This is completely different from the mechanisms of action of the current immune checkpoint blockade therapies, representing a new form of cancer immunotherapy, namely, the immune ecotherapy.
- 28 January 2026
- Published by Frontiers Media SA in Frontiers in Molecular Biosciences
- Vol. 12
Open AccessPlasmodium infection fully activates the immune system in peripheral blood and tumor microenvironment in a murine Lewis lung cancer model
Background: Plasmodium infection has been proven to activate antitumor immune responses. This study comprehensively analyzes the immune cell populations in peripheral blood and tumor microenvironment to elucidate the potential immunological mechanisms by which Plasmodium infection inhibits tumor growth. Methods: We established a subcutaneous Lewis lung cancer model in C57BL/6J mice and treated them with intraperitoneal injection of Plasmodium yoelii . The long and short diameters of tumors were measured. Then, high-dimensional flow cytometry was used to analyze the T cell subsets, macrophages and myeloid-derived suppressor cells (MDSCs) in peripheral blood and tumor tissues. Immunosuppression-related phosphorylated signal transducer and activator of transcription 3 (pSTAT3) and TGFβ in tumor tissues were also measured through Western blotting assay. Results: Plasmodium infection inhibited the growth of Lewis lung cancer in mice. The infection increased in the numbers of CD3 + T cells, including CD4 + and CD8 + T, CD4 + central memory T (Tcm), CD4 + effector memory T (Tem), CD8 + Tcm, CD8 + Tem, CD8 + virtual memory T (Tvm), CD8 + short-lived effector cells (SLEC), and CD8 + memory precursor effector cells (CD8 + MPEC) in peripheral blood. Concurrently, the infection also increased the numbers of CD3 + T cells, including CD4 + and CD8 + T, CD4 + Tcm, CD4 + Tem, CD4 + tissue resident memory T (Trm), CD8 + Tcm, CD8 + Tem, CD8 + Trm and CD8 + SLEC in tumor tissues. In addition, Plasmodium infection reduced the expression levels of PD-1 on CD4 + and CD8 + T, the number of polymorphonuclear MDSCs, and increased the ratio of M1/M2 macrophages in the tumor tissues. The initial mechanism study revealed that Plasmodium infection significantly reduced the expression levels of pSTAT3 and TGFβ in tumor tissues, providing direct evidence that Plasmodium infection activated the antitumor immune responses. Conclusion: Based on our past and current studies, we can draw the following conclusion: Plasmodium infection fully remodels and activates the immune system, targets and inhibits the entire tumor ecosystem through the key signals of pSTAT3 and TGFβ. This is completely different from the mechanisms of action of the current immune checkpoint blockade therapies, representing a new form of cancer immunotherapy, namely, the immune ecotherapy.
- Open Access
- 6 January 2024
- Published by Springer Nature in BMC Immunology
- Vol. 25 (1) , 1-9
The predictive value of peripheral blood CD4 cells ATP concentration for immune-related adverse events in advanced non-small cell lung cancer patients
Lung cancer with the highest incidence and mortality in the world. Immune checkpoint inhibitors (ICIs), can bring long-term survival benefits to patients, but also can bring immune-related adverse events (irAEs) in some patients during therapy. Therefore, the aim of this study was to investigate the predictive effect of peripheral blood WBC, NLR, sATPCD4 and nATPCD4 on irAEs in advanced non-small cell lung cancer (NSCLC). Clinical data of 112 patients with advanced NSCLC who were treated with PD -1/PD -L1 inhibitor in the Fifth Affiliated Hospital of Guangzhou Medical University from December 15, 2019 to April 30, 2023 were retrospectively analyzed. These patients were divided into the irAEs group (n = 27) and non-irAEs group (n = 85). The clinical data of the two groups were compared. Receiver operating characteristic (ROC) curves were drawn to determine the threshold value of baseline peripheral blood parameters to predict the occurrence of irAEs. Multivariate logistic regression analysis was used to explore the relationship between peripheral blood markers and the incidence of irAEs. The patient characteristics have no significant difference between irAEs and non-irAEs group. But the baseline peripheral blood WBC, sATPCD4 and nATPCD4 of patients in the irAEs group were higher than those in the non-irAEs group (p < 0.05), and the NLR in irAEs group was similar to in the non-irAEs group (p = 0.639).Univariate analysis showed that high WBC, sATPCD4 and nATPCD4 may the risk factors for the occurrence of irAEs (p < 0.05). Multivariate logistic regression analysis showed that high sATPCD4 and nATPCD4 were independent risk factors for the occurrence of irAEs (p < 0.05). The best critical values of WBC, sATPCD4 and nATPCD4 before treatment for predicting the occurrence of irAEs were 8.165 × 109cells/L (AUC = 0.705) ,484.5 ng/mL (AUC = 0.777), and 156 ng/mL (AUC = 0.840), respectively. sATPCD4 and nATPCD4 were independent risk factors for the occurrence of irAEs in advanced NSCLC patients. This discovery provides a new method to predict the occurrence of irAEs in patients. Based on the prediction results, corresponding treatment measures can be taken to reduce the incidence of adverse events.
- 6 January 2024
- Published by Springer Nature in BMC Immunology
- Vol. 25 (1) , 1-9
Open AccessThe predictive value of peripheral blood CD4 cells ATP concentration for immune-related adverse events in advanced non-small cell lung cancer patients
Lung cancer with the highest incidence and mortality in the world. Immune checkpoint inhibitors (ICIs), can bring long-term survival benefits to patients, but also can bring immune-related adverse events (irAEs) in some patients during therapy. Therefore, the aim of this study was to investigate the predictive effect of peripheral blood WBC, NLR, sATPCD4 and nATPCD4 on irAEs in advanced non-small cell lung cancer (NSCLC). Clinical data of 112 patients with advanced NSCLC who were treated with PD -1/PD -L1 inhibitor in the Fifth Affiliated Hospital of Guangzhou Medical University from December 15, 2019 to April 30, 2023 were retrospectively analyzed. These patients were divided into the irAEs group (n = 27) and non-irAEs group (n = 85). The clinical data of the two groups were compared. Receiver operating characteristic (ROC) curves were drawn to determine the threshold value of baseline peripheral blood parameters to predict the occurrence of irAEs. Multivariate logistic regression analysis was used to explore the relationship between peripheral blood markers and the incidence of irAEs. The patient characteristics have no significant difference between irAEs and non-irAEs group. But the baseline peripheral blood WBC, sATPCD4 and nATPCD4 of patients in the irAEs group were higher than those in the non-irAEs group (p < 0.05), and the NLR in irAEs group was similar to in the non-irAEs group (p = 0.639).Univariate analysis showed that high WBC, sATPCD4 and nATPCD4 may the risk factors for the occurrence of irAEs (p < 0.05). Multivariate logistic regression analysis showed that high sATPCD4 and nATPCD4 were independent risk factors for the occurrence of irAEs (p < 0.05). The best critical values of WBC, sATPCD4 and nATPCD4 before treatment for predicting the occurrence of irAEs were 8.165 × 109cells/L (AUC = 0.705) ,484.5 ng/mL (AUC = 0.777), and 156 ng/mL (AUC = 0.840), respectively. sATPCD4 and nATPCD4 were independent risk factors for the occurrence of irAEs in advanced NSCLC patients. This discovery provides a new method to predict the occurrence of irAEs in patients. Based on the prediction results, corresponding treatment measures can be taken to reduce the incidence of adverse events.
- Open Access
- 13 December 2023
- Published by Springer Nature in Research Square
The Potential of CD4+ T cells ATP level to indicate the Progression in NSCLC Patients
Purpose A new immune function assessment method (sATPCD4) has been proposed to monitor the immune suppression status in non-small cell lung cancer (NSCLC) patients after chemotherapy. In this study, we attempted to determine the utility of this functional assay in assessing the risk of disease progression in NSCLC patients. Methods A retrospective analysis of clinical data from 89 advanced NSCLC patients who received chemotherapy at the Fifth Affiliated Hospital of Guangzhou Medical University from March 15, 2022, to March 30, 2023. These patients were divided into a disease progression group (PD, n = 21) and a disease stability group (Non-PD, n = 68). Clinical data between the two groups were compared. Receiver operating characteristic (ROC) curves were plotted to determine the thresholds of baseline peripheral blood parameters for predicting disease progression occurrence. Multivariate logistic regression analysis was employed to investigate the relationship between peripheral blood markers and the incidence of disease progression. Results After chemotherapy, there were significant differences in the mean values of WBC, nATPCD4, and sATP CD4 between patients who experienced disease progression (PD) and those who remained stable (Non-PD) (P < 0.05). In the PD group, sATPCD4 levels significantly decreased post-chemotherapy, while in the Non-PD group, sATPCD4 levels showed an increase. The threshold for predicting disease progression after chemotherapy, as determined by ROC analysis, was 224.5 ng/ml (AUC = 0.887, 95% CI, 0.811–0.963). Patients in the low-immunity group (ATP < 224.5 ng/ml) were more likely to experience disease progression compared to the high-immunity group (ATP > 224.5 ng/ml) (P < 0.0001). Multivariate logistic regression analysis indicated that sATPCD4 levels were an independent predictor of disease progression in NSCLC patients Conclusions Immune function testing has the potential to assess the risk of disease progression in NSCLC patients
- 13 December 2023
- Published by Springer Nature in Research Square
Open AccessThe Potential of CD4+ T cells ATP level to indicate the Progression in NSCLC Patients
Purpose A new immune function assessment method (sATPCD4) has been proposed to monitor the immune suppression status in non-small cell lung cancer (NSCLC) patients after chemotherapy. In this study, we attempted to determine the utility of this functional assay in assessing the risk of disease progression in NSCLC patients. Methods A retrospective analysis of clinical data from 89 advanced NSCLC patients who received chemotherapy at the Fifth Affiliated Hospital of Guangzhou Medical University from March 15, 2022, to March 30, 2023. These patients were divided into a disease progression group (PD, n = 21) and a disease stability group (Non-PD, n = 68). Clinical data between the two groups were compared. Receiver operating characteristic (ROC) curves were plotted to determine the thresholds of baseline peripheral blood parameters for predicting disease progression occurrence. Multivariate logistic regression analysis was employed to investigate the relationship between peripheral blood markers and the incidence of disease progression. Results After chemotherapy, there were significant differences in the mean values of WBC, nATPCD4, and sATP CD4 between patients who experienced disease progression (PD) and those who remained stable (Non-PD) (P < 0.05). In the PD group, sATPCD4 levels significantly decreased post-chemotherapy, while in the Non-PD group, sATPCD4 levels showed an increase. The threshold for predicting disease progression after chemotherapy, as determined by ROC analysis, was 224.5 ng/ml (AUC = 0.887, 95% CI, 0.811–0.963). Patients in the low-immunity group (ATP < 224.5 ng/ml) were more likely to experience disease progression compared to the high-immunity group (ATP > 224.5 ng/ml) (P < 0.0001). Multivariate logistic regression analysis indicated that sATPCD4 levels were an independent predictor of disease progression in NSCLC patients Conclusions Immune function testing has the potential to assess the risk of disease progression in NSCLC patients
- Open Access
- 13 September 2023
- Published by Elsevier in Cancer Treatment and Research Communications
- Vol. 37, 100758
The progresses of relevant factors on the efficacy of immune checkpoint inhibitors in the non-small cell lung cancer patients
- 13 September 2023
- Published by Elsevier in Cancer Treatment and Research Communications
- Vol. 37, 100758
Open AccessThe progresses of relevant factors on the efficacy of immune checkpoint inhibitors in the non-small cell lung cancer patients
- Open Access
- 12 September 2023
- Published by Springer Nature in Research Square
The predictive value of peripheral blood CD4 cells ATP concentration for immune-related adverse events in advanced non-small cell lung cancer patients
Objective Lung cancer with the highest incidence and mortality in the world. Immune checkpoint inhibitors (ICIs), can bring long-term survival benefits to patients, but also can bring immune-related adverse events (irAEs) in some patients during therapy. Therefore, the aim of this study was to investigate the predictive effect of peripheral blood WBC, NLR, sATPCD4 and nATPCD4 on irAEs in advanced non-small cell lung cancer (NSCLC) Methods Clinical data of 112 patients with advanced NSCLC who were treated with PD -1/PD -L1 inhibitor in the Fifth Affiliated Hospital of Guangzhou Medical University from December 15, 2019 to April 30, 2023 were retrospectively analyzed. These patients were divided into the irAEs group (n = 27) and non-irAEs group (n = 85). The clinical data of the two groups were compared. Receiver operating characteristic (ROC) curves were drawn to determine the threshold value of baseline peripheral blood parameters to predict the occurrence of irAEs. Multivariate logistic regression analysis was used to explore the relationship between peripheral blood markers and the incidence of irAEs. Results The patient characteristics have no significant difference between irAEs and non-irAEs group. But the baseline peripheral blood WBC, sATPCD4 and nATPCD4 of patients in the irAEs group were higher than those in the non-irAEs group (p < 0.05), and the NLR in irAEs group was similar to in the non-irAEs group (p = 0.639).Univariate analysis showed that high WBC, sATPCD4 and nATPCD4 may the risk factors for the occurrence of irAEs (p < 0.05). Multivariate logistic regression analysis showed that high sATPCD4 and nATPCD4 were independent risk factors for the occurrence of irAEs (p < 0.05). The best critical values of WBC, sATPCD4 and nATPCD4 before treatment for predicting the occurrence of irAEs were 8.165×109cells/L (AUC = 0.705) ,484.5 ng/mL (AUC = 0.777), and 156 ng/mL (AUC = 0.840), respectively. Conclusions sATPCD4 and nATPCD4 were independent risk factors for the occurrence of irAEs in advanced NSCLC patients. This discovery provides a new method to predict the occurrence of irAEs in patients. Based on the prediction results, corresponding treatment measures can be taken to reduce the incidence of adverse events
- 12 September 2023
- Published by Springer Nature in Research Square
Open AccessThe predictive value of peripheral blood CD4 cells ATP concentration for immune-related adverse events in advanced non-small cell lung cancer patients
Objective Lung cancer with the highest incidence and mortality in the world. Immune checkpoint inhibitors (ICIs), can bring long-term survival benefits to patients, but also can bring immune-related adverse events (irAEs) in some patients during therapy. Therefore, the aim of this study was to investigate the predictive effect of peripheral blood WBC, NLR, sATPCD4 and nATPCD4 on irAEs in advanced non-small cell lung cancer (NSCLC) Methods Clinical data of 112 patients with advanced NSCLC who were treated with PD -1/PD -L1 inhibitor in the Fifth Affiliated Hospital of Guangzhou Medical University from December 15, 2019 to April 30, 2023 were retrospectively analyzed. These patients were divided into the irAEs group (n = 27) and non-irAEs group (n = 85). The clinical data of the two groups were compared. Receiver operating characteristic (ROC) curves were drawn to determine the threshold value of baseline peripheral blood parameters to predict the occurrence of irAEs. Multivariate logistic regression analysis was used to explore the relationship between peripheral blood markers and the incidence of irAEs. Results The patient characteristics have no significant difference between irAEs and non-irAEs group. But the baseline peripheral blood WBC, sATPCD4 and nATPCD4 of patients in the irAEs group were higher than those in the non-irAEs group (p < 0.05), and the NLR in irAEs group was similar to in the non-irAEs group (p = 0.639).Univariate analysis showed that high WBC, sATPCD4 and nATPCD4 may the risk factors for the occurrence of irAEs (p < 0.05). Multivariate logistic regression analysis showed that high sATPCD4 and nATPCD4 were independent risk factors for the occurrence of irAEs (p < 0.05). The best critical values of WBC, sATPCD4 and nATPCD4 before treatment for predicting the occurrence of irAEs were 8.165×109cells/L (AUC = 0.705) ,484.5 ng/mL (AUC = 0.777), and 156 ng/mL (AUC = 0.840), respectively. Conclusions sATPCD4 and nATPCD4 were independent risk factors for the occurrence of irAEs in advanced NSCLC patients. This discovery provides a new method to predict the occurrence of irAEs in patients. Based on the prediction results, corresponding treatment measures can be taken to reduce the incidence of adverse events
- Open Access
- 12 December 2022
- Published by Springer Nature in Molecular Medicine
- Vol. 28 (1) , 1-13
Oxidized LDL promotes EMS-induced angiogenesis by increasing VEGF-A expression and secretion by endometrial cells
Background: Endometriosis (EMS) is a “tumour-like” gynaecological disease with distant metastasis, and studies have shown that EMS can induce distant metastasis through vascular vessels, but the driving factors and their mechanism are not clear. Methods: We used an EMS animal model and gene knockout technique to explore the role of EMS-induced angiogenesis in EMS metastasis in vivo and in vitro and clarify the role and molecular mechanism of oxLDL in promoting EMS-induced angiogenesis. Results: We found that microvascular density (MVD) in metastasized ectopic endometrium and eutopic endometrial tissue was higher than that in normal endometrial tissue, and plasma oxLDL was positively correlated with the distant metastasis of EMS. Furthermore, we clarified that oxLDL enhanced the MVD of endometrial tissue by increasing VEGF-A expression and secretion in endometrial cells. Finally, we illustrated the mechanism by which oxLDL promotes VEGF-A expression through the AKT-HIF-1α signalling pathway. Conclusion: OxLDL is a risk factor promoting distant EMS metastasis by increasing VEGF-A expression and secretion through AKT-HIF-1α signalling. This finding may provide theoretical support and therapeutic targets for the clinical prevention and treatment of EMS.
- 12 December 2022
- Published by Springer Nature in Molecular Medicine
- Vol. 28 (1) , 1-13
Open AccessOxidized LDL promotes EMS-induced angiogenesis by increasing VEGF-A expression and secretion by endometrial cells
Background: Endometriosis (EMS) is a “tumour-like” gynaecological disease with distant metastasis, and studies have shown that EMS can induce distant metastasis through vascular vessels, but the driving factors and their mechanism are not clear. Methods: We used an EMS animal model and gene knockout technique to explore the role of EMS-induced angiogenesis in EMS metastasis in vivo and in vitro and clarify the role and molecular mechanism of oxLDL in promoting EMS-induced angiogenesis. Results: We found that microvascular density (MVD) in metastasized ectopic endometrium and eutopic endometrial tissue was higher than that in normal endometrial tissue, and plasma oxLDL was positively correlated with the distant metastasis of EMS. Furthermore, we clarified that oxLDL enhanced the MVD of endometrial tissue by increasing VEGF-A expression and secretion in endometrial cells. Finally, we illustrated the mechanism by which oxLDL promotes VEGF-A expression through the AKT-HIF-1α signalling pathway. Conclusion: OxLDL is a risk factor promoting distant EMS metastasis by increasing VEGF-A expression and secretion through AKT-HIF-1α signalling. This finding may provide theoretical support and therapeutic targets for the clinical prevention and treatment of EMS.
- Open Access
- 1 August 2021
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 567, 222-229
CCT5 interacts with cyclin D1 promoting lung adenocarcinoma cell migration and invasion
- 1 August 2021
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 567, 222-229
Open AccessCCT5 interacts with cyclin D1 promoting lung adenocarcinoma cell migration and invasion
- Open Access
- 1 March 2021
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 23, 324-335
VPS33B modulates c-Myc/p53/miR-192-3p to target CCNB1 suppressing the growth of non-small cell lung cancer
- 1 March 2021
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 23, 324-335
Open AccessVPS33B modulates c-Myc/p53/miR-192-3p to target CCNB1 suppressing the growth of non-small cell lung cancer